Rheumatoid Arthritis Clinical Trials

Showing 17361-17380 of 47,334 trials

Oxytocin and Cognitive Control in Adult ADHD

NCT03136263

This is a randomized, double-blind, placebo-controlled crossover study of single-dose intranasal oxytocin (24 IU) in 18-55 year-old men with attention deficit/hyperactivity disorder (ADHD). Following a screening visit to determine eligibility, participants will return for two main study visits. During the main study visits, study participants will receive either oxytocin (Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland) or placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy), followed by assessments of cognitive control over attention and behavior. Twenty-four participants will be randomized 1:1 to one of two drug orders, i.e., oxytocin - placebo or placebo - oxytocin. In an additional neuroimaging substudy, a subset of participants will undergo task-based and resting-state functional magnetic resonance imaging (fMRI) following oxytocin/placebo administration to investigate the effects of oxytocin on fMRI activation and functional connectivity within the cognitive control network.

Attention Deficit/Hyperactivity Disorder

Massachusetts General Hospital24 participantsStarted Dec 2017

Boston, Massachusetts, United States

COMPLETEDPhase 2

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

NCT01928576

Response Rate

Non-Small Cell Lung CancerEpigenetic Therapy

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins143 participantsStarted Nov 2013

Los Angeles, California, United States • Washington D.C., District of Columbia, United States • Baltimore, Maryland, United States +2 more locations

COMPLETEDNA

Study Comparing At-Home Mobile Spirometry to In-Clinic in Moderate Asthma Participants Taking Long-Acting Beta Agonist

NCT05757908

The goal of this interventional study is to compare at-home mobile spirometry to in-clinic spirometry in participants with moderate asthma while taking a long-acting beta agonist (LABA). The main questions it aims to answer are: * Do at-home mobile spirometry and in-clinic spirometry assessments show a similar treatment effect (measured changes in FEV1) with the addition of LABA? * Is at-home mobile spirometry as accurate as in-clinic spirometry in showing treatment effects (changes in FEV1)? Participants will be asked to: * Take standard of care LABA treatment once or twice a day * Complete at-home mobile spirometry testing twice a day * Complete asthma questionnaires twice a day * Complete device use questionnaires * Wear a wrist device (like a watch) to track physical activity and vital signs * Visit the clinic for in-clinic spirometry testing once a week for 8 weeks

Moderate Asthma

Koneksa Health29 participantsStarted Apr 2023

Birmingham, Alabama, United States • Columbus, Georgia, United States • North Dartmouth, Massachusetts, United States +6 more locations

Oxytocin and Cognitive Control in Adult ADHD

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

Study Comparing At-Home Mobile Spirometry to In-Clinic in Moderate Asthma Participants Taking Long-Acting Beta Agonist

Related Searches

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

Integrated Pulmonary Index as a Predictor of Respiratory Compromise in Critically Ill Patients

Comparison of US Bilateral Erector Spinae Plane Block, US Bilateral Quadratus Lumborum Block and Lumbar Epidural for Postoperative Analgesia in Patients Undergoing Total Abdominal Hysterectomy

Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy

FEmale Metabolic Risk and Androgens: an Irish Longitudinal (FEMAIL) Study

Remote Ischemic Conditioning in HSCT

A Clinical Trial of COVAC-2 in Adults

Clinical Evaluation of the ID NOW™ CT/NG Test

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

EASE-SOT Pilot Study

Effect of Virtual Reality Exercise Versus Aerobic Training on Performance and Endurance in Physical Therapy Students

Enhanced Rehabilitation After Major Trauma (PROPERLY)

Switching to Potential Reduced Exposure Products in Adult Smokers

The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning

Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia

Brachial Right Ventricle - Endomyocardial Biopsy